Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of Obesity on GVHD in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies.
Transplant Cell Ther
January 2025
Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Background: The relationship between obesity and graft-versus-host disease (GVHD) has been studied in both preclinical and clinical studies with varying results.
Objectives: We aimed to investigate the impact of obesity, as measured by body mass index (BMI), on the incidence, severity, and response to therapy of GVHD in a contemporary cohort.
Study Design: We conducted a retrospective study of patients undergoing allogeneic hematopoietic cell transplant (HCT) for acute myelogenous leukemia and myelodysplastic syndrome between January 2010 and December 2021 at the Cleveland Clinic.
Proteomic analysis for busulfan-induced spermatogenesis disorder.
Ann Med
December 2025
School of Life Science, Bengbu Medical University, Bengbu, China.
Background: Busulfan is the most commonly used drug for the treatment of chronic myelogenous leukemia and pretreatment for hematopoietic stem cell transplantation, which can damage the reproductive and immune system. However, little is known about the protein expression profiling in busulfan treated testis.
Methods: This research studies the proteomics for busulfan-induced spermatogenesis disorder.
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML).
Expert Rev Hematol
January 2025
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Introduction: Chronic myeloid leukemia (CML) represents one of the first neoplasms whose molecular pathogenesis was successfully unraveled, with tyrosine kinase inhibitors (TKIs) representing one of the first-targeted therapies. TKIs have revolutionized long-term outcomes of CML patients and their life expectancy. Nonetheless, a minority of patients will develop TKI resistance due to a complex and multifactorial process that ultimately leads to the emergence of an unresponsive cancer clone.
View Article and Find Full Text PDFAdvanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.
Drugs
January 2025
Division of Hematology & Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, Milwaukee, WI, 53226, USA.
A small number of patients with chronic myeloid leukemia (CML) either present with or progress to the accelerated phase (AP) or blast phase (BP). This occurs in approximately 4-7% of patients with CML. Most patients who progress to BP-CML are of myeloid lineage, while approximately 30% are of lymphoid lineage.
View Article and Find Full Text PDF[Research on the clinical characteristics and prognosis of children with chronic myeloid leukemia in the blast phase].
Zhonghua Xue Ye Xue Za Zhi
October 2024
Peking University People's Hospital, Department of Pediatrics, Beijing 100044, China.
To explore the clinical characteristics and prognosis of children with chronic myeloid leukemia in the blast phase (CML-BP) . The clinical characteristics, treatment measures, and survival outcomes of 28 children with CML-BP were analyzed in our hospital from January 2008 to November 2022. The male to female ratio of the 28 children with CML-BP was 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!